Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …

It is well-known that elevated lipoprotein (a)—Lp (a)—levels are associated with a higher
risk of cardiovascular (CV) mortality and all-cause mortality, although a standard …

Summary Low-density lipoprotein (LDL)-cholesterol (LDL-c) and lipoprotein (a)[Lp (a)] are
independent cardiovascular risk factors. Reduction of LDL-c leads to reduction in …

Abstract Purpose of Review Apheresis is a treatment option for severe dyslipidemia which
has been introduced approximately 40 years ago to clinical practice. This article reviews …

Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide.
Several clinical and epidemiological studies have demonstrated that an elevated plasma …

Population, genetic, and clinical studies demonstrated a causative and continuous, from
other plasma lipoproteins independent relationship between elevated plasma lipoprotein …

Background: Dyslipidemia is the main factor involved in the occurrence and progression of
coronary artery disease. Objective: The research strategy is aimed at analyzing new data on …

There is a direct relationship between the duration and level of exposure to low density
lipoprotein cholesterol (LDL-C) levels over one's lifespan and cardiovascular events. Early …

BACKGROUND: Lipoprotein (a)(Lp (a)) is an inherited, independent, and causal risk factor
for atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To assess the burden of …